Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Gerald M. Borok"'
Autor:
Debra A. Wertz, Sanjay Gandhi, Vincent J. Willey, S.A. Kamat, Michael F. Bullano, Gerald M. Borok, Kenneth McDonough
Publikováno v:
American Journal of Health-System Pharmacy. 64:276-284
Purpose. The effectiveness of rosuvastatin versus atorvastatin in reducing lipid levels and achieving low-density-lipoprotein (LDL) cholesterol goals in patients treated in a usual care setting was studied. Methods. Electronic medical and pharmacy ad
Autor:
Christina Fontes, Gerald M. Borok, Eunice Chang, Setareh A. Williams, Caron Ory, Kenneth McDonough
Publikováno v:
Disease Management & Health Outcomes. 14:37-44
To examine factors associated with HMG-CoA reductase inhibitor (statin) management and the effect of therapeutic modifications on patients’ abilities to reach their low-density lipoprotein-cholesterol (LDL-C) goal in a sample of managed care enroll
Autor:
Nazia Rashid, Daniel Lang, Gerald M. Borok, Dan Ershoff, Paul T Le, Robert Mendes, Amanda Bruno, Kristin P Jazdzewski, Brian Meissner, Niu Fang, Jaejin An, Diana Dills
Publikováno v:
Journal of the American College of Cardiology. 63(12)
Increased time in therapeutic range (TTR) on warfarin is often used as a balance between preventing stroke without excess bleeding. This study evaluated stroke or systemic embolism (SE) and bleeding risks of antithrombotic therapies in non-valvular a
Autor:
Marian Rewers, Elizabeth J. Mayer, Richard N. Bergman, George Howard, Gerald M. Borok, Joseph V. Selby, Lynne E. Wagenknecht, Steven M. Haffner, Leora Henkin, Mohammed F. Saad, Richard F. Hamman, Peter J. Savage
Publikováno v:
Annals of Epidemiology. 5:464-472
The Insulin Resistance Atherosclerosis Study (IRAS) is the first epidemiologic study designed to assess the relationships between insulin resistance, insulinemia, glycemia, other components of the insulin resistance syndrome, and prevalent cardiovasc
Autor:
Girma Wolde-Tsadik, Linda K. Fishman, John C. Beck, David B. Reuben, Yunbao Liu, Gerald M. Borok, Daniel H. Ershoff, Virginia L. Ambrosini, Laurence Z. Rubenstein
Publikováno v:
New England Journal of Medicine. 332:1345-1350
Background Although many studies describe benefits from the comprehensive assessment of elderly patients by an interdisciplinary team (comprehensive geriatric assessment), the most supportive evidence for the process has come from programs that rely
Autor:
Girma Wolde-Tsadik, David B. Reuben, John C. Beck, Gerald M. Borok, Bens Pardamean, Laurence Z. Rubenstein, Betty Hammond
Publikováno v:
Journal of the American Geriatrics Society. 40:482-488
Objective To determine the yield of standardized targeting criteria for identifying hospitalized HMO patients who are at high risk for mortality and nursing home placement and, therefore, may be appropriate for comprehensive geriatric assessment. Des
Autor:
Gerald M. Borok, Tara K. Knight, Richard O'Connor, Ole Hauch, Tom Dow, Michael B. Nichol, Gail Wygant
Publikováno v:
The Annals of pharmacotherapy. 42(1)
Background: Prior research suggests that receiving specialized anticoagulation services enables patients to achieve better clinical outcomes. Objective: To assess the quality of anticoagulation therapy in patents with atrial fibrillation who were enr
Autor:
Gerald M. Borok, Daniel M. Huse, Xue Song, Ken Mcdonough, Setareh A. Williams, Ronald J. Ozminkowski
Publikováno v:
Journal of occupational and environmental medicine. 48(10)
OBJECTIVE The objective of this study was to examine the impact of introducing rosuvastatin calcium on direct and indirect costs among patients at high risk for coronary heart disease. METHODS An economic simulation model was developed to project the
Autor:
Gerald M. Borok, Jonathan Maguire, Kenneth McDonough, Ronald J. Ozminkowski, Daniel M. Huse, Xue Song, Setareh A. Williams
Publikováno v:
Clinical therapeutics. 28(9)
Background: High blood cholesterol is a major modifiable risk factor for coronary heart disease (CHD) and stroke. Objective: The aim of this study was to estimate the economic impact of rosuvastatin calcium use in patients at high risk for CHD and st
Autor:
Gerald M. Borok, Kenneth McDonough, Michael F. Bullano, Debra A. Wertz, Vincent J. Willey, Sanjay Gandhi, Grace W Yang, S.A. Kamat
Publikováno v:
Pharmacotherapy. 26(4)
Study Objective. To compare, in a usual care setting, the effects of rosuvastatin and other 3-hydroxy-3-methylglutaryl coenzyme A inhibitors (statins) on lipid levels and on goal attainment of low-density lipoprotein cholesterol (LDL) levels from the